Answers are grounded in this paper and cite their sources.
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: